DMCC Act Overhauls UK Consumer Law and Expands Consumer Rights

The Competition and Markets Authority (CMA) has outlined its initial plans as the new digital markets competition regime comes into force.

Here’s why Section 227(1)(c) of the DMCC Act matters:

➡️ A business practice is guilty of a misleading omission if it fails to identify its commercial intent. ➡️ The CMA is now empowered to impose penalties on firms that fail to provide required information during investigations into anti-competitive behaviour or consumer protection breaches.

This marks a significant step forward in ensuring transparency and accountability in consumer-facing industries.

💬 Why it matters for patient brokering:

Patient brokering often misleads vulnerable individuals by hiding financial incentives, directly impacting life-changing decisions.

The transactional decision test: Patients trust advice that appears impartial, but without disclosure of commercial intent, their ability to make informed choices is compromised.

Transparency isn’t optional—it’s the law.

This new legislation offers greater protection for those in vulnerable situations, particularly individuals affected by addiction and mental health challenges.

➡️  Patient brokers must disclose financial incentives and operate with integrity. Lives are at stake, and informed decisions must be the priority.

https://www.gov.uk/government/news/cma-sets-out-initial-plans-as-new-digital-markets-competition-regime-comes-into-force